MedTrace Logo

Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations

NCT01307930 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-01-09

Study results available
· View outcomes & findings →

Summary

This study will find how weight affects the dosing of a drug called anidulafungin. Currently, the amount of anidulafungin a patient receives is the same regardless of the patient's weight. BMI groups were for enrollment purposes only and not used for ordinal data analysis.

Conditions

Interventions

DRUG

Anidulafungin

Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Ronald Hall, PharmD, MSCS · Texas Tech UHSC

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01307930 on ClinicalTrials.gov